Status:
WITHDRAWN
Stellate Ganglion Block for Hot Flushes in Men Treated With ADT
Lead Sponsor:
Rijnstate Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of locally advanced and metastatic prostate cancer. Hot flushes and night sweats are one of the main side-effects...
Detailed Description
Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of locally advanced and metastatic prostate cancer. Hot flushes and night sweats are one of the main side-effects...
Eligibility Criteria
Inclusion
- Male
- Age: \>18 years
- Mean daily flush frequency of 10 or more and a hot flush score of 15 or more
- Treatment with ADT because of prostate cancer
- Absence of any other cause of flushing
Exclusion
- Use of medication that affects flushing: oestrogens, progestogens, clonidine, naloxone, paroxetine, fluoxetine, venlafaxine, gabapentin, luteinizing hormone-releasing hormone receptor antagonist
- Still receiving chemotherapy of radiotherapy
- Psychiatric disease
- Any unstable concurrent disease
- Allergic reactions against bupivacaine or contrast media.
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02295163
Start Date
July 1 2014
End Date
January 1 2021
Last Update
March 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rijnstate Hospital
Arnhem, Gelderland, Netherlands, 6815 AD